Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Urinary frequency

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    422 result(s) found for: Urinary frequency. Displaying page 9 of 22.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2011-006041-14 Sponsor Protocol Number: FINA-007 Start Date*: 2012-10-26
    Sponsor Name:MerLion Pharmaceuticals GmbH
    Full Title: A Multi-Dose, Double-Blind, Double-Dummy, Active Control, Randomized Clinical (Phase II) Study of Two Dosing Regimens of Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Requiring...
    Medical condition: Complicated Urinary Tract Infection and/or Acute Polyonephritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-000222-38 Sponsor Protocol Number: P00048GP404 Start Date*: 2014-06-03
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: PERMIXON® 160 mg hard capsule versus placebo in the treatment of symptomatic lower urinary tract symptoms due to benign prostatic hyperplasia. Single-blind placebo run-in period then double-blin...
    Medical condition: PERMIXON® 160 mg hard capsule versus placebo in the treatment of symptomatic lower urinary tract symptoms due to benign prostatic hyperplasia.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004872 10004447 Benign prostatic hypertrophy LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed) ES (Completed) CZ (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-001152-35 Sponsor Protocol Number: UX003-CL201 Start Date*: 2013-08-02
    Sponsor Name:Ultragenyx Pharmaceutical Inc.
    Full Title: An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of UX003 rhGUS Enzyme Replacement Therapy in Patients with MPS 7
    Medical condition: Mucopolysaccharidosis type 7 (MPS 7, Sly syndrome)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-001627-11 Sponsor Protocol Number: 617-EC-006 Start Date*: 2005-10-03
    Sponsor Name:Yamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V., as of August 2005)
    Full Title: A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract sympto...
    Medical condition: LUTS (lower urinary tract symptoms) associated with BPH (benign prostatic hyperplasia)
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SK (Completed) IE (Completed) GB (Completed) CZ (Completed) DK (Completed) ES (Completed) HU (Completed) FI (Completed) IT (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000910-12 Sponsor Protocol Number: HT011 Start Date*: 2020-07-01
    Sponsor Name:Helperby Therapeutics Ireland Limited
    Full Title: A Double-blinded, Parallel-group, Randomized, Active-controlled Phase 2 Clinical Trial to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intravenous HY-001 Versus Standard Colis...
    Medical condition: complicated urinary tract infection (cUTI).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10046577 Urinary tract infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000938-19 Sponsor Protocol Number: 4PH/2012/002 Start Date*: 2012-06-11
    Sponsor Name:NOVINTETHICAL PHARMA SAGL
    Full Title: Safety and Efficacy of tablets containing extract of Hibiscus Sabdariffa (HS) and Propoli versus placebo in the treatment of the cystitis with Ciproxin
    Medical condition: patients with diagnosys of cystitis confirmed by urine culture
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004249-33 Sponsor Protocol Number: A8881001 Start Date*: 2005-12-14
    Sponsor Name:Pfizer Limited
    Full Title: A phase 2, 26 week, multicenter, randomized double blind, placebo controlled, crossover study evaluating the efficacy and safety of tolterodine, pregabalin and a tolterodine-pregabalin combination ...
    Medical condition: Overactive bladder syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.0 10059617 LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) SK (Completed) SE (Completed) CZ (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022611-19 Sponsor Protocol Number: XEN-D0501-CL-03 Start Date*: 2011-01-07
    Sponsor Name:Xention Limited
    Full Title: A Phase 2a, multicentre, parallel-group, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of 2 doses of XEN-D0501 in the treatment of idiopathic overactive bla...
    Medical condition: Overactive bladder (OAB)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) BE (Completed) EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005565-13 Sponsor Protocol Number: 17000139BLC2002 Start Date*: 2021-10-26
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are...
    Medical condition: Muscle-Invasive Urothelial Carcinoma of the Bladder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    21.0 100000004864 10046720 Urothelial carcinoma bladder stage II LLT
    21.0 100000004864 10046721 Urothelial carcinoma bladder stage III LLT
    21.0 100000004864 10046722 Urothelial carcinoma bladder stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004650-93 Sponsor Protocol Number: botuline5 Start Date*: 2007-10-10
    Sponsor Name:University Medical Center Groningen
    Full Title: The effect of Botulinum toxin A injections for overactive bladder on detrusor contractility
    Medical condition: Neurogenic or idiopathic overactive bladder, not adequately responding to anticholinergic therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003398-24 Sponsor Protocol Number: OAB/AB/07 Start Date*: 2008-01-21
    Sponsor Name:The Whittington Hospital NHS Trust
    Full Title: A randomised, double blind validation of the significance of occult pyuria for the symptoms of the overactive bladder
    Medical condition: The overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000906-12 Sponsor Protocol Number: AQX-1125-301 Start Date*: 2016-09-07
    Sponsor Name:Aquinox Pharmaceuticals (Canada) Inc.
    Full Title: The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targ...
    Medical condition: Interstitial Cystitis/Bladder Pain Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10071166 Bladder pain syndrome LLT
    20.0 100000004857 10008927 Chronic interstitial cystitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) HU (Completed) CZ (Completed) LV (Prematurely Ended) GB (Prematurely Ended) BE (Completed) ES (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003294-33 Sponsor Protocol Number: RVT-901-3004 Start Date*: 2018-07-06
    Sponsor Name:Urovant Sciences GmbH
    Full Title: An International Phase 3, Randomized, Double-Blind, Active (Tolterodine)-Controlled Multicenter Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Patients with Symptoms o...
    Medical condition: Adult men and women with either: * OAB Wet * OAB Dry
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) HU (Prematurely Ended) LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-002981-39 Sponsor Protocol Number: v1.1aug05 Start Date*: 2008-09-19
    Sponsor Name:University Hospitals of Leicester NHS Trust
    Full Title: Randomised trial of detrusor botulinum toxin injection (BOTOX®) compared to placebo in women with idiopathic detrusor overactivity
    Medical condition: Detrusor overactivity which is a disease of bladder function where unprovoked contractions of the detrusor muscle are generated during the storage phase of micturition. Symptoms include frequency, ...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-004011-30 Sponsor Protocol Number: 987654321 Start Date*: 2005-12-02
    Sponsor Name:Gwent Healthcare NHS Trust
    Full Title: A prospective open study evaluating the use of botulinum toxin in patients with overactive bladder as an alternative to other conservative treatments.
    Medical condition: Overactive bladder syndrome is characterized by a combination of urinary frequency, urgency and urge incontinence.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000940-17 Sponsor Protocol Number: 64Cu Start Date*: 2018-05-07
    Sponsor Name:
    Full Title: Phase IIa clinical study of 64 CuCl2: efficacy and safety of a new tracer for urologic tumors
    Medical condition: Genitourinary tract tumors in male patients
    Disease:
    Population Age: Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003712-12 Sponsor Protocol Number: 20160801 Start Date*: 2016-12-20
    Sponsor Name:Södersjukhuset AB
    Full Title: Implementation project of AFL in clinical practice
    Medical condition: Women with arrested labour
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004560-29 Sponsor Protocol Number: AGO/2011/010 Start Date*: 2011-10-25
    Sponsor Name:Ghent University Hospital
    Full Title: Desmopressin melt therapy in nocturnal polyuria patients: pharmacodynamic study
    Medical condition: Noctural polyuria
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10064016 Nocturnal polyuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005735-91 Sponsor Protocol Number: 178-CL-101 Start Date*: 2013-11-12
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabeg...
    Medical condition: Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) NL (Completed) CZ (Completed) HU (Completed) LV (Completed) SE (Completed) IT (Completed) EE (Completed) FI (Completed) SK (Completed) SI (Completed) DK (Completed) ES (Completed) LT (Completed) PL (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-005457-22 Sponsor Protocol Number: TA-5538-03 Start Date*: 2006-03-30
    Sponsor Name:Tanabe Seiyaku Co., Ltd
    Full Title: A phase IIa, multi-centre, randomised, placebo-controlled, double-blind, parallel group study of TA-5538, in patients with overactive bladder
    Medical condition: A phase IIa, multi-centre, randomised, placebo-controlled, double-blind, parallel group study of TA-5538, in patients with overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059617 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) FI (Completed) HU (Completed) CZ (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 24 13:45:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA